| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal ID1596: Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly |
|
Medicine details |
|
| Medicine name | ropeginterferon alfa-2b (Besremi®) |
| Formulation | 250 micrograms/0.5 mL solution for injection |
| Reference number | 3217 |
| Indication | Monotherapy in adults for the treatment of polycythaemia vera without symptomatic splenomegaly |
| Company | AOP Orphan Pharmaceuticals AG |
| BNF chapter | Immunological products & vaccines |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 08/06/2021 |
| NICE guidance | ID1596: Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly |